{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:03:31Z","timestamp":1791169411202,"version":"4.1.0"},"reference-count":37,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,2,26]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>In a Ph+ ALL mouse model, dasatinib inhibition of the BCR-ABL kinase resensitizes residual leukemic B cells to Janus kinase inhibition. Dasatinib, ruxolitinib, and dexamethasone together limit emergence of dasatinib-resistant BCR-ABL mutants and extend long-term survival.<\/jats:p>","DOI":"10.1182\/blood-2014-09-601062","type":"journal-article","created":{"date-parts":[[2014,12,12]],"date-time":"2014-12-12T23:37:54Z","timestamp":1418427474000},"page":"1444-1451","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":38,"title":["Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL"],"prefix":"10.1182","volume":"125","author":[{"given":"Iris","family":"Appelmann","sequence":"first","affiliation":[{"name":"Cancer Biology & Genetics Program, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory D.","family":"Rillahan","sequence":"additional","affiliation":[{"name":"Cancer Biology & Genetics Program, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"de Stanchina","sequence":"additional","affiliation":[{"name":"Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Carbonetti","sequence":"additional","affiliation":[{"name":"Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Chen","sequence":"additional","affiliation":[{"name":"Cancer Biology & Genetics Program, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott W.","family":"Lowe","sequence":"additional","affiliation":[{"name":"Cancer Biology & Genetics Program, and"},{"name":"Howard Hughes Medical Institute, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5516-6206","authenticated-orcid":false,"given":"Charles J.","family":"Sherr","sequence":"additional","affiliation":[{"name":"Cancer Biology & Genetics Program, and"},{"name":"Howard Hughes Medical Institute, and"},{"name":"Department of Tumor Cell Biology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111819555405900_B1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev.immunol.22.012703.104753","article-title":"The BCR-ABL story: bench to bedside and back.","volume":"22","author":"Wong","year":"2004","journal-title":"Annu Rev Immunol"},{"issue":"12","key":"2019111819555405900_B2","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1182\/blood-2009-12-261586","article-title":"First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.","volume":"116","author":"Ravandi","year":"2010","journal-title":"Blood"},{"issue":"25","key":"2019111819555405900_B3","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","article-title":"Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.","volume":"118","author":"Fo\u00e0","year":"2011","journal-title":"Blood"},{"issue":"7","key":"2019111819555405900_B4","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2012-11-466482","article-title":"Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.","volume":"122","author":"Ravandi","year":"2013","journal-title":"Blood"},{"key":"2019111819555405900_B5","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1101\/sqb.2008.73.039","article-title":"The INK4-ARF (CDKN2A\/B) locus in hematopoiesis and BCR-ABL-induced leukemias.","volume":"73","author":"Williams","year":"2008","journal-title":"Cold Spring Harb Symp Quant Biol"},{"issue":"11","key":"2019111819555405900_B6","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1101\/gad.1673908","article-title":"Failure of CDKN2A\/B (INK4A\/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL.","volume":"22","author":"Mullighan","year":"2008","journal-title":"Genes Dev"},{"issue":"7191","key":"2019111819555405900_B7","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature06866","article-title":"BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.","volume":"453","author":"Mullighan","year":"2008","journal-title":"Nature"},{"issue":"3","key":"2019111819555405900_B8","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/ni.2828","article-title":"Stage-specific control of early B cell development by the transcription factor Ikaros.","volume":"15","author":"Schwickert","year":"2014","journal-title":"Nat Immunol"},{"issue":"8","key":"2019111819555405900_B9","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1084\/jem.20090004","article-title":"Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function.","volume":"206","author":"Trageser","year":"2009","journal-title":"J Exp Med"},{"issue":"17","key":"2019111819555405900_B10","doi-asserted-by":"crossref","first-page":"6688","DOI":"10.1073\/pnas.0602030103","article-title":"Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.","volume":"103","author":"Williams","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"18","key":"2019111819555405900_B11","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1101\/gad.1588607","article-title":"Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia.","volume":"21","author":"Williams","year":"2007","journal-title":"Genes Dev"},{"issue":"13","key":"2019111819555405900_B12","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1182\/blood-2010-08-301267","article-title":"Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia.","volume":"117","author":"Boulos","year":"2011","journal-title":"Blood"},{"issue":"24","key":"2019111819555405900_B13","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"2019111819555405900_B14","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","article-title":"Jaks and STATs: biological implications.","volume":"16","author":"Leonard","year":"1998","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"2019111819555405900_B15","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1084\/jem.183.3.811","article-title":"Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr\/Abl.","volume":"183","author":"Carlesso","year":"1996","journal-title":"J Exp Med"},{"issue":"6","key":"2019111819555405900_B16","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1182\/blood.V95.6.2118","article-title":"STAT5 activation contributes to growth and viability in Bcr\/Abl-transformed cells.","volume":"95","author":"Sillaber","year":"2000","journal-title":"Blood"},{"issue":"49","key":"2019111819555405900_B17","doi-asserted-by":"crossref","first-page":"31704","DOI":"10.1074\/jbc.271.49.31704","article-title":"P210 and P190(BCR\/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members.","volume":"271","author":"Ilaria","year":"1996","journal-title":"J Biol Chem"},{"issue":"23","key":"2019111819555405900_B18","doi-asserted-by":"crossref","first-page":"9312","DOI":"10.1073\/pnas.85.23.9312","article-title":"Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr\/abl protein.","volume":"85","author":"Daley","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2019111819555405900_B19","first-page":"535","article-title":"Critical role for cyclin D2 in BCR\/ABL-induced proliferation of hematopoietic cells.","volume":"62","author":"Jena","year":"2002","journal-title":"Cancer Res"},{"issue":"9","key":"2019111819555405900_B20","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1182\/blood-2012-06-440230","article-title":"Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia.","volume":"122","author":"Koss","year":"2013","journal-title":"Blood"},{"issue":"15","key":"2019111819555405900_B21","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.","volume":"115","author":"Quint\u00e1s-Cardama","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2019111819555405900_B22","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111819555405900_B23","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S1470-2045(10)70114-5","article-title":"Glucocorticoid use in acute lymphoblastic leukaemia.","volume":"11","author":"Inaba","year":"2010","journal-title":"Lancet Oncol"},{"issue":"5","key":"2019111819555405900_B24","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0092-8674(00)80452-3","article-title":"Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF.","volume":"91","author":"Kamijo","year":"1997","journal-title":"Cell"},{"key":"2019111819555405900_B25","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0076-6879(87)50085-4","article-title":"Long-term culture of murine bone marrow precursors of B lymphocytes.","volume":"150","author":"Whitlock","year":"1987","journal-title":"Methods Enzymol"},{"issue":"45","key":"2019111819555405900_B26","doi-asserted-by":"crossref","first-page":"16870","DOI":"10.1073\/pnas.0606509103","article-title":"Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.","volume":"103","author":"Hu","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"2019111819555405900_B27","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1182\/blood-2013-03-487728","article-title":"Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain.","volume":"122","author":"Soverini","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2019111819555405900_B28","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/cncr.28522","article-title":"Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.","volume":"120","author":"Soverini","year":"2014","journal-title":"Cancer"},{"issue":"12","key":"2019111819555405900_B29","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1182\/blood-2002-10-3059","article-title":"The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr\/Abl-induced leukemia.","volume":"101","author":"Wolff","year":"2003","journal-title":"Blood"},{"issue":"3","key":"2019111819555405900_B30","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1124\/jpet.109.154781","article-title":"P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.","volume":"330","author":"Chen","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"2019111819555405900_B31","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1158\/1078-0432.CCR-08-2253","article-title":"Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.","volume":"15","author":"Lagas","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"51","key":"2019111819555405900_B32","doi-asserted-by":"crossref","first-page":"19466","DOI":"10.1073\/pnas.0609239103","article-title":"Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants.","volume":"103","author":"Skaggs","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"16","key":"2019111819555405900_B33","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1128\/MCB.02202-05","article-title":"Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.","volume":"26","author":"Griswold","year":"2006","journal-title":"Mol Cell Biol"},{"issue":"4","key":"2019111819555405900_B34","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/sj.leu.2404151","article-title":"The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib.","volume":"20","author":"Miething","year":"2006","journal-title":"Leukemia"},{"issue":"9","key":"2019111819555405900_B35","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1182\/blood-2013-12-545640","article-title":"JAK2\/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.","volume":"124","author":"Gallipoli","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111819555405900_B36","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"issue":"11","key":"2019111819555405900_B37","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.","volume":"371","author":"Roberts","year":"2014","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/125\/9\/1444\/1388339\/1444.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/125\/9\/1444\/1388339\/1444.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T20:04:39Z","timestamp":1574107479000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/125\/9\/1444\/34204\/Janus-kinase-inhibition-by-ruxolitinib-extends"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,26]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,2,26]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2014-09-601062","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,26]]}}}